Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients

The Study of Efficacy and Adverse Effects of Prapchompoothaweep Remedy Crude Drug and Loratadine for Treatment in Allergic Rhinitis Patients (Clinical Trials Phase II)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20181220002

Enrollment

Unknown

Registered

2018-12-20

Start date

2017-11-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis Loratadine&#44

Interventions

Take Prapchompoothaweep remedy capsule at 1&#44

000 mg for 3 times a day before meals.,Take Loratadine 10 mg once a day before meals.

Experimental Drug,Experimental Drug

Prapchompoothaweep remedy,Loratadine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-70 years old. 2. Patients with history of allergic rhinitis based on ARIA guidelines. (itching and nasal obstruction, watery nasal discharge, sneezing ,congestion) 3. Patients with moderate allergic rhinitis was diagnosed by physicians. 4. Have no nasal septum perforation, nasal polyp or sinus surgery. 5. Have no serious medical conditions: Heart disease, Liver disease, Renal disease, Hypertension, Peptic Ulcer and Gastroesophageal reflux disease (GERD), severe Asthma, Tuberculosis. 6. Have normal range of Hematology test for Liver and Renal function. 7. No Pregnant or Lactation. 8. Do not taking a medicine constantly. 9. Volunteers are willing to participate this study.

Exclusion criteria

Exclusion criteria: 1. Allergic reactions to Prapchompoothaweep remedy and Loratadine. 2. Allergic reaction to dairy products. 3. Have severe urticaria and anaphylaxis. 4. Have a serious condition of immunodeficiency disease: HIV in the previous month before being recruited in the study. 5. Participate in another study.

Design outcomes

Primary

Measure	Time frame
Nasal cavity Change from baseline at 6 weeks week-0, week-3 and week-6 Using an Acoustic Rhinometry to evaluate nasal symptoms,Nasal symptoms Change from baseline at 6 weeks. week-0, week-3 and week-6 Using Total Nasal Symptom Score Questionnaire.	—

Secondary

Measure	Time frame
Assessment of well-being of volunteer that change from baseline at 6 weeks. week-0, week-3 and week-6 Using Rhinoconjunctivitis Questionnaire of Life (Thai Version copyright by Chaweewan Bunnag MD)	—

Countries

Thailand

Contacts

Public ContactWaipoj Chanvimalueng

Thammasat University

waipoj@tu.ac.th02-926-9839

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Feb 7, 2026